Zogenix, Inc. Announces Publication of SUMAVEL(R) DosePro(R) Phase 4 Clinical Data

SAN DIEGO, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today the publication of its SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery system Phase 4 clinical study results. The study, which demonstrated increased patient overall satisfaction, confidence and preference for SUMAVEL DosePro amongst current triptan users in the treatment of multiple migraine attacks, will be published in the September issue of the peer-reviewed journal Headache, The Journal of Head and Face Pain. Headache is the official publication of the American Headache Society (AHS).